NAFT500 (adult)
ApprovedSmall molecule
NAFT500 (adult) is one of 21 small molecule programs targeting Tinea Pedis. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Tinea Pedis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lamisil
NovartisPhase 3
Nizoral
WWim Janssens
Phase 3
Luzu
BBausch Health Americas, Inc.
Approved
Inomax
MMallinckrodt
Phase 2
NAFT500 (adult)
MMerz North America, Inc.
Approved
Ciclopirox Olamine
AAtlas Molecular Pharma
Phase 3
Terbinafine Hydrochloride
NovartisPhase 2
NAFT-500
MMerz North America, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NAFT500 (adult). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMerz North America, Inc.